News | Clinical Decision Support | February 05, 2019

Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support

Planned software designed to sort and score cases automatically with Transpara deep learning technology from ScreenPoint Medical

Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support

February 4, 2019 — Siemens Healthineers showcased the new planned artificial intelligence (AI)-based features with its mammography reading and reporting solution, syngo.Breast Care, at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago.1 These features are designed to provide physicians with interactive decision support.

AI features can help assist clinicians, particularly in cancer screening. A large number of mammograms are performed each day to screen for breast cancer, which means radiologists must accurately interpret hundreds of images daily. Additionally, the increased use of 3-D breast tomosynthesis adds to the number of images to be read. The new version of syngo.Breast Care is designed to give radiologists interactive clinical decision support.

AI-based algorithms are designed to help evaluate individual lesions and provide a system evaluation for 2-D mammograms or tomosynthesis. A peer-reviewed scientific study2 demonstrated increased sensitivity and specificity with the use of AI-based support.

Also, the planned software is designed to sort cases automatically and score those cases with a numerical value between 1 and 10. The case score is designed to take into account any existing lesions, microcalcifications and other abnormalities.   

syngo.Breast Care’s planned new SmartSort technology is designed for radiologists to rank exams according to their preferences based on these case scores. For example, critical cases can be moved immediately to the top to receive priority.

Siemens Healthineers collaborated with ScreenPoint Medical and plans to integrate interactive decision support in syngo.Breast Care. The company’s mammography reading software, Transpara, is based on deep learning and has been trained with over 1 million images.

Transpara received FDA 510(k) clearance for 2-D reading in late November.

For more information: www.usa.siemens.com/healthcare

References

1. Syngo.Breast Care VB40 - powered by Transpara, ScreenPoint Medical - is currently under development. It is not for sale in the U.S. Its future availability cannot be guaranteed.

2 Rodriguez-Ruiz A., Gubern-Merida A., Lang K., et al.: Detecting breast cancer in mammography: a deep learning-based computer system versus 101 radiologists (RSNA abstract 2018).

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
January 12, 2021 — The U.S.
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...